Last reviewed · How we verify
CD7 CAR T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD7 CAR T cells (CD7 CAR T cells) — iCell Gene Therapeutics. Genetically modified T cells that express a chimeric antigen receptor targeting CD7 on malignant T cells to eliminate cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD7 CAR T cells TARGET | CD7 CAR T cells | iCell Gene Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD7 CAR T cells CI watch — RSS
- CD7 CAR T cells CI watch — Atom
- CD7 CAR T cells CI watch — JSON
- CD7 CAR T cells alone — RSS
Cite this brief
Drug Landscape (2026). CD7 CAR T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/cd7-car-t-cells. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing